VAsopressin and STeroids in addition to Adrenaline in cardiac arrest-a randomized clinical trial. VAST-A
Phase 1
- Conditions
- Cardiac arrestTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- CTIS2022-500137-89-00
- Lead Sponsor
- Tiohundra AB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 1400
Inclusion Criteria
In hospital cardiac arrest patients meeting criteria for adrenaline administration according to current ERC guidelines are eligible for the study
Exclusion Criteria
Patient under 18 years of age, Women considered of childbearing potential (WOCBP) i. e. premenopausal women
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The primary objective of the study is to determine whether the use of a combination of adrenaline, vasopressin and steroids will increase 30 days survival in cardiac arrest patients compared to standard adrenaline alone;Secondary Objective: Neurological outcome at 30 days (mRS and GOS-E) ROSC Survival at 6 months Neurological outcome (mRS and GOS-E) at 6 months;Primary end point(s): Survival at 30 days
- Secondary Outcome Measures
Name Time Method